The trial is set to last two years from September, with more than 3,000 patients in France expected to be the first to receive the new drugs.
Drug safety agency ANSM confirmed that it would be open to authorising “foreign products”, and said that it had already “auditioned” seven companies last year.
Several Canadian companies are already seeking to enter the market, along with Dutch firm Bedrocan and British group Emmac Life Sciences.
Sign up to our free weekly e-newsletter
Subscribe to access all our online articles and receive our printed monthly newspaper The Connexion at your home. News analysis, features and practical help for English-speakers in France